» Articles » PMID: 24666474

Radiologic Features of Breast Cancer After Mantle Radiation Therapy for Hodgkin Disease: a Study of 230 Cases

Overview
Journal Radiology
Specialty Radiology
Date 2014 Mar 27
PMID 24666474
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To retrospectively review diagnostic mammography in women diagnosed with breast cancer who previously had mantle field radiation therapy for Hodgkin disease in England and Wales over a period of 30 years.

Materials And Methods: From a national cohort study of 5002 women treated with supradiaphragmatic radiation therapy when they were younger than 36 years (mean, 22.1 years) during 1956-2003, 392 patients developed breast cancer. With ethics committee approval and informed consent, mammograms were obtained that showed 230 tumors in 222 (56.6%) patients from 95 hospitals, and the size and appearance of each carcinoma was recorded by two breast radiologists. Comparison was made with a historical report of more than 1000 general-population breast cancers by using Pearson χ(2) test.

Results: Thirty-eight tumors were occult on mammograms. Mean tumor maximum diameter was 12.3 mm (n = 81) on oblique view. The quadrant distribution of the tumors was significantly different (P < .001) from the historic controls, and chest radiation therapy patients had a greater proportion of tumors in the upper outer (66.9% [107 of 160] vs 48.7% [385 of 784]) and, to a lesser extent, lower inner (10.6% [17 of 160] vs 7.8% [61 of 784]) quadrants. The dominant radiologic feature was of an irregular mass (56.8% [109 of 192]) followed by microcalcifications (25.0% [48 of 192]).

Conclusion: This study suggests that in patients who previously underwent mantle radiation therapy for Hodgkin disease, breast cancers are more commonly seen within the upper outer quadrants than are cancers in the general population. Poorly defined masses were the most common appearance.

Citing Articles

A Case Report on Breast Cancer Following Mantle Radiation for Hodgkin Lymphoma: Screening and Management.

Mansour Y, Akinleye A Cureus. 2024; 16(6):e62584.

PMID: 39027736 PMC: 11257641. DOI: 10.7759/cureus.62584.


T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.

Wang J, Shen K, Mu W, Li W, Zhang M, Zhang W Front Immunol. 2022; 13:873789.

PMID: 35572515 PMC: 9094425. DOI: 10.3389/fimmu.2022.873789.


Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.

Chelmow D, Pearlman M, Young A, Bozzuto L, Dayaratna S, Jeudy M Obstet Gynecol. 2020; 135(6):1457-1478.

PMID: 32459439 PMC: 7253192. DOI: 10.1097/AOG.0000000000003889.


Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy.

Russell N, Krul I, van Eggermond A, Aleman B, Cooke R, Kuiper S Clin Transl Radiat Oncol. 2018; 7:20-27.

PMID: 29594225 PMC: 5862668. DOI: 10.1016/j.ctro.2017.09.004.


Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma survivors): recommendations for surveillance from the Italian College of Breast Radiologists by SIRM.

Mariscotti G, Belli P, Bernardi D, Brancato B, Calabrese M, Carbonaro L Radiol Med. 2016; 121(11):834-837.

PMID: 27406629 DOI: 10.1007/s11547-016-0667-9.